Last reviewed · How we verify

Tyrosine kinase inhibitor (TKI) — Competitive Intelligence Brief

Tyrosine kinase inhibitor (TKI) (tyrosine-kinase-inhibitor-tki) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TKIs. Area: Oncology.

preclinical TKIs Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tyrosine kinase inhibitor (TKI) (tyrosine-kinase-inhibitor-tki) — Pfizer Inc.. TKIs

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tyrosine kinase inhibitor (TKI) TARGET tyrosine-kinase-inhibitor-tki Pfizer Inc. preclinical TKIs

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TKIs class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tyrosine kinase inhibitor (TKI) — Competitive Intelligence Brief. https://druglandscape.com/ci/tyrosine-kinase-inhibitor-tki. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing